Asset Details
Do you wish to reserve the book?
Cancer treatment-induced thrombocytopenia: diagnosis, mechanisms and management
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Cancer treatment-induced thrombocytopenia: diagnosis, mechanisms and management
Do you wish to request the book?
Cancer treatment-induced thrombocytopenia: diagnosis, mechanisms and management
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Cancer treatment-induced thrombocytopenia: diagnosis, mechanisms and management
2025
Overview
Cancer treatment-induced thrombocytopenia (CTIT) is a common adverse effect in malignant tumor patients, significantly increasing the risk of bleeding and negatively impacting treatment efficacy and quality of life. Current treatment options for CTIT primarily include platelet transfusion, recombinant human interleukin-11 (rhIL-11), recombinant human thrombopoietin (rhTPO) and thrombopoietin receptor agonists (TPO-RAs). However, these methods have their limitations; for instance, platelet transfusions may cause adverse reactions, and the efficacy and safety of rhTPO and TPO-RAs remain controversial. This review aims to summarize the current treatment landscape for CTIT and explore new therapeutic advancement, including the potential role of traditional Chinese medicine, in order to provide more effective treatment strategies for clinical practice.
Publisher
Frontiers Media SA,Frontiers Media S.A
Subject
/ Animals
/ Antineoplastic Agents - adverse effects
/ chemotherapy-induced thrombocytopenia (CIT)
/ CTIT
/ Humans
/ immune checkpoint inhibitors-induced thrombocytopenia (ICIIT)
/ Leukemia
/ Lymphoma
/ Patients
/ Purpura
/ Receptors, Thrombopoietin - agonists
/ Spleen
/ Thrombocytopenia - chemically induced
/ Thrombocytopenia - diagnosis
/ Thrombopoietin - therapeutic use
/ TPO-RAs
/ Traditional Chinese medicine
/ traditional Chinese medicine (TCM)
/ Tumors
